within Pharmacolibrary.Drugs.ATC.C;

model C01CA19
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1.0,
    Cl             = 0.05,
    adminDuration  = 600,
    adminMass      = 0.0003,
    adminCount     = 1,
    Vd             = 0.00045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fenoldopam is a selective dopamine D1-receptor agonist used primarily as a rapid-acting antihypertensive agent. It is used in the management of severe hypertension, including hypertensive emergencies, by causing vasodilation. Fenoldopam is administered intravenously and is approved for use in clinical settings such as hospitals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after intravenous infusion.</p><h4>References</h4><ol><li><p>O&#x27;Neill, KE, et al., &amp; Court, MH (2016). The pharmacokinetics of intravenous fenoldopam in healthy, awake cats. <i>Journal of veterinary pharmacology and therapeutics</i> 39(2) 202–204. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12274&quot;>10.1111/jvp.12274</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26763106/&quot;>https://pubmed.ncbi.nlm.nih.gov/26763106</a></p></li><li><p>Brogden, RN, &amp; Markham, A (1997). Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. <i>Drugs</i> 54(4) 634–650. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199754040-00008&quot;>10.2165/00003495-199754040-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9339965/&quot;>https://pubmed.ncbi.nlm.nih.gov/9339965</a></p></li><li><p>Bloom, CA, et al., &amp; Court, MH (2012). Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs. <i>Journal of veterinary pharmacology and therapeutics</i> 35(3) 224–230. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.2011.01319.x&quot;>10.1111/j.1365-2885.2011.01319.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21732952/&quot;>https://pubmed.ncbi.nlm.nih.gov/21732952</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01CA19;
